Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $92.00 price objective on the stock.

Several other research firms have also weighed in on APLS. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a hold rating to a buy rating and lifted their target price for the stock from $68.00 to $80.00 in a report on Monday, February 5th. The Goldman Sachs Group lifted their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a buy rating in a report on Tuesday, January 9th. Raymond James lifted their price target on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a strong-buy rating in a research note on Thursday, January 11th. Needham & Company LLC reissued a buy rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Mizuho reissued a neutral rating and issued a $60.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus target price of $78.60.

Apellis Pharmaceuticals Stock Down 0.6 %

NASDAQ:APLS opened at $51.50 on Monday. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $6.21 billion, a P/E ratio of -11.50 and a beta of 0.88. The stock’s fifty day simple moving average is $61.22 and its 200-day simple moving average is $57.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.50) earnings per share. Equities research analysts expect that Apellis Pharmaceuticals will post -1.33 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In related news, insider Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Timothy Eugene Sullivan sold 3,551 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $230,815.00. Following the transaction, the chief financial officer now directly owns 95,675 shares in the company, valued at approximately $6,218,875. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 406,651 shares of company stock valued at $25,130,257. 7.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Apellis Pharmaceuticals by 66.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company’s stock worth $302,760,000 after acquiring an additional 1,840,498 shares during the period. Jennison Associates LLC boosted its holdings in shares of Apellis Pharmaceuticals by 79.8% during the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after acquiring an additional 1,571,606 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Apellis Pharmaceuticals by 109.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after acquiring an additional 1,121,497 shares during the period. Norges Bank bought a new stake in shares of Apellis Pharmaceuticals during the fourth quarter worth approximately $54,164,000. Finally, Morgan Stanley boosted its holdings in shares of Apellis Pharmaceuticals by 112.6% during the third quarter. Morgan Stanley now owns 1,608,996 shares of the company’s stock worth $61,206,000 after acquiring an additional 852,331 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).